187 related articles for article (PubMed ID: 26296210)
1. Gut Homing Molecule Regulation of the Pathogenesis and Treatment of Inflammatory Bowel Diseases.
Evans-Marin HL; Cong Y
Inflamm Allergy Drug Targets; 2015; 14(1):4-12. PubMed ID: 26296210
[TBL] [Abstract][Full Text] [Related]
2. Glucocorticoids Suppress CCR9-Mediated Chemotaxis, Calcium Flux, and Adhesion to MAdCAM-1 in Human T Cells.
Wendt E; White GE; Ferry H; Huhn M; Greaves DR; Keshav S
J Immunol; 2016 May; 196(9):3910-9. PubMed ID: 27016601
[TBL] [Abstract][Full Text] [Related]
3. In Vivo Generation of Gut-Homing Regulatory T Cells for the Suppression of Colitis.
Xu Y; Cheng Y; Baylink DJ; Wasnik S; Goel G; Huang M; Cao H; Qin X; Lau KW; Chan C; Koch A; Pham LH; Zhang J; Li CH; Wang X; Berumen EC; Smith J; Tang X
J Immunol; 2019 Jun; 202(12):3447-3457. PubMed ID: 31053627
[TBL] [Abstract][Full Text] [Related]
4. IRAK1 Drives Intestinal Inflammation by Promoting the Generation of Effector Th Cells with Optimal Gut-Homing Capacity.
Heiseke AF; Jeuk BH; Markota A; Straub T; Lehr HA; Reindl W; Krug AB
J Immunol; 2015 Dec; 195(12):5787-94. PubMed ID: 26561545
[TBL] [Abstract][Full Text] [Related]
5. The Heteromeric Complex Formed by Dopamine Receptor D
Osorio-Barrios F; Navarro G; Campos J; Ugalde V; Prado C; Raïch I; Contreras F; López E; Espinoza A; Lladser A; Franco R; Pacheco R
Cell Mol Gastroenterol Hepatol; 2021; 12(2):489-506. PubMed ID: 33864900
[TBL] [Abstract][Full Text] [Related]
6. Development of gut-homing receptors on circulating B cells during infancy.
Lundell AC; Rabe H; Quiding-Järbrink M; Andersson K; Nordström I; Adlerberth I; Wold AE; Rudin A
Clin Immunol; 2011 Jan; 138(1):97-106. PubMed ID: 21075690
[TBL] [Abstract][Full Text] [Related]
7. Skin- and gut-homing molecules on human circulating γδ T cells and their dysregulation in inflammatory bowel disease.
Mann ER; McCarthy NE; Peake ST; Milestone AN; Al-Hassi HO; Bernardo D; Tee CT; Landy J; Pitcher MC; Cochrane SA; Hart AL; Stagg AJ; Knight SC
Clin Exp Immunol; 2012 Nov; 170(2):122-30. PubMed ID: 23039882
[TBL] [Abstract][Full Text] [Related]
8. Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease.
Lamb CA; O'Byrne S; Keir ME; Butcher EC
J Crohns Colitis; 2018 Aug; 12(suppl_2):S653-S668. PubMed ID: 29767705
[TBL] [Abstract][Full Text] [Related]
9. Gut-tropic T cells that express integrin α4β7 and CCR9 are required for induction of oral immune tolerance in mice.
Cassani B; Villablanca EJ; Quintana FJ; Love PE; Lacy-Hulbert A; Blaner WS; Sparwasser T; Snapper SB; Weiner HL; Mora JR
Gastroenterology; 2011 Dec; 141(6):2109-18. PubMed ID: 21925467
[TBL] [Abstract][Full Text] [Related]
10. Differential T cell homing to colon vs. small intestine is imprinted by local CD11c
Dzutsev A; Hogg A; Sui Y; Solaymani-Mohammadi S; Yu H; Frey B; Wang Y; Berzofsky JA
J Leukoc Biol; 2017 Dec; 102(6):1381-1388. PubMed ID: 28951425
[TBL] [Abstract][Full Text] [Related]
11. Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells.
Jovani M; Danese S
Curr Drug Targets; 2013 Nov; 14(12):1433-43. PubMed ID: 23980911
[TBL] [Abstract][Full Text] [Related]
12. Retinoic acid imprints gut-homing specificity on T cells.
Iwata M; Hirakiyama A; Eshima Y; Kagechika H; Kato C; Song SY
Immunity; 2004 Oct; 21(4):527-38. PubMed ID: 15485630
[TBL] [Abstract][Full Text] [Related]
13. Immunopathogenesis of inflammatory bowel diseases: functional role of T cells and T cell homing.
Zundler S; Neurath MF
Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S19-28. PubMed ID: 26458165
[TBL] [Abstract][Full Text] [Related]
14. Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases.
Saruta M; Papadakis KA
Gastroenterol Clin North Am; 2014 Sep; 43(3):581-601. PubMed ID: 25110260
[TBL] [Abstract][Full Text] [Related]
15. The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti-integrin therapies.
Dotan I; Allez M; Danese S; Keir M; Tole S; McBride J
Med Res Rev; 2020 Jan; 40(1):245-262. PubMed ID: 31215680
[TBL] [Abstract][Full Text] [Related]
16. CCR9 and inflammatory bowel disease.
Koenecke C; Förster R
Expert Opin Ther Targets; 2009 Mar; 13(3):297-306. PubMed ID: 19236152
[TBL] [Abstract][Full Text] [Related]
17. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases.
Danese S; Panés J
Gastroenterology; 2014 Nov; 147(5):981-9. PubMed ID: 25220794
[TBL] [Abstract][Full Text] [Related]
18. Homing of immune cells: role in homeostasis and intestinal inflammation.
Hart AL; Ng SC; Mann E; Al-Hassi HO; Bernardo D; Knight SC
Inflamm Bowel Dis; 2010 Nov; 16(11):1969-77. PubMed ID: 20848507
[TBL] [Abstract][Full Text] [Related]
19. The Complexity of alpha E beta 7 Blockade in Inflammatory Bowel Diseases.
Smids C; Horjus Talabur Horje CS; van Wijk F; van Lochem EG
J Crohns Colitis; 2017 Apr; 11(4):500-508. PubMed ID: 27660340
[TBL] [Abstract][Full Text] [Related]
20. Blockade of αEβ7 integrin suppresses accumulation of CD8
Zundler S; Schillinger D; Fischer A; Atreya R; López-Posadas R; Watson A; Neufert C; Atreya I; Neurath MF
Gut; 2017 Nov; 66(11):1936-1948. PubMed ID: 27543429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
